Hongria - hongarès - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

+pharma arzneimittel gmbh - montelukast -

Hongria - hongarès - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

kéri pharma hungary kft. - rosuvastatin -

Hongria - hongarès - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

kéri pharma hungary kft. - rosuvastatin -

Hongria - hongarès - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

kéri pharma hungary kft. - rosuvastatin -

Unió Europea - hongarès - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - gyógyszerek obstruktív légúti betegségek, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Unió Europea - hongarès - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - gyógyszerek obstruktív légúti betegségek, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Unió Europea - hongarès - EMA (European Medicines Agency)

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianémiás készítmények - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

Unió Europea - hongarès - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - egyéb szívkészítmények - treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Unió Europea - hongarès - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - pikkelysömör - immunszuppresszánsok - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Unió Europea - hongarès - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - alvási beavatkozás és karbantartás - pszicholeptikumok - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.